Skip to Content
Merck
  • Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.

Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.

Anticancer research (2014-04-30)
Marit Arnes, Bodil Hvingel, Anne Orbo
ABSTRACT

The main objective was to investigate if occurrence of hyperplastic polyps was reduced by use of the levonorgestrel-impregnated intrauterine system (LNG-IUS, Mirena®; Bayer) and if the LNG-IUS was more effective compared to oral medroxyprogesterone acetate (MPA) or observation-only. Patients (N=59) with hyperplastic polyps were given LNG-IUS, 10 mg oral MPA taken 10 days per cycle, or had observation-only for six months. Diagnosis of histological specimens was performed by light microscopy according to the WHO classification and D-score prior to and after six months therapy. No polyps were found in women treated with LNG-IUS (18/18). Five women treated with cyclic MPA (5/20, 25%) and two (2/21, 9%) with observation had normal endometrium without polyps after six months. No former study has shown that LNG-IUS is effective at reducing the occurrence of hyperplastic endometrial polyps. The effect is superior to that of oral progestin and observation-only.

MATERIALS
Product Number
Brand
Product Description

Supelco
ORBO 23 2-HMP on Amberlite XAD®-2 (20/40), 120/60 mg, W,W,W separators, O.D. × L 6 mm × 85 mm, pkg of 25 ea
Sigma-Aldrich
Medroxyprogesterone 17-acetate, ≥97% (HPLC)
Supelco
D(−)-Norgestrel, analytical standard
Supelco
Medroxyprogesterone 17-acetate, VETRANAL®, analytical standard
Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard
Levonorgestrel for system suitability 2, European Pharmacopoeia (EP) Reference Standard
USP
Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard
Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard
Levonorgestrel, European Pharmacopoeia (EP) Reference Standard
Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard